E-resources
Peer reviewed
Open access
-
Xia, Yi; Wang, Li; Ding, Kaiyang; Wu, Jiazhu; Yin, Hua; Hu, Maogui; Shen, Haorui; Liang, Jinhua; Chen, Ruize; Li, Yue; Zhu, Huayuan; Li, Jianyong; Xu, Wei
Chinese medical journal, 06/2023, Volume: 136, Issue: 12Journal Article
Chidamide, a novel subtype-selective histone deacetylase inhibitor (HDACi), can directly inhibit tumor cell cycle progression, induce tumor cell apoptosis, and restore the sensitivity of drug-resistant tumor cells to drugs by loosening chromatin and exposing deoxyribonucleic acid (DNA). The protocol of this study was approved by the Institutional Review Board of Jiangsu Province Hospital and Anhui Provincial Cancer Hospital (No. 2017-SR-271). ...63 patients were included in the per-protocol set (PPS) Supplementary Figure 1, http://links.lww.com/CM9/B617. ...chidamide with anti-programmed cell death protein 1 achieved an objective response rate of 58.3% and a CR rate of 44.4% in treating advanced and relapsed/refractory ENKTL.
